Cargando…
Treatment duration with immune-based therapies in Cancer: an enigma
Unlike chemotherapy treatments that target the tumor itself (rather nonspecifically), immune-based therapies attempt to harness the power of an individual patient’s immune system to combat cancer. Similar to chemotherapeutic agents, the dosage and Administration section of labeling for all five curr...
Autores principales: | Bantia, Shanta, Choradia, Nirmal |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282359/ https://www.ncbi.nlm.nih.gov/pubmed/30518409 http://dx.doi.org/10.1186/s40425-018-0465-0 |
Ejemplares similares
-
Correction to: Treatment duration with immune-based therapies in Cancer: an enigma
por: Bantia, Shanta, et al.
Publicado: (2019) -
Purine nucleoside phosphorylase inhibitors - an immunotherapy with novel mechanism of action for the treatment of melanoma
por: Bantia, Shanta
Publicado: (2015) -
The enigma of forgetting
por: Wixted, John T.
Publicado: (2022) -
Deciphering the enigma of neuroendocrine prostate cancer
por: Karzai, Fatima, et al.
Publicado: (2022) -
The Enigma of Vascular Calcifications
por: Sprague, Stuart M.
Publicado: (2020)